Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Ninosu, Nadia Nicole [VerfasserIn]   i
 Melchers, Susanne [VerfasserIn]   i
 Kappenstein, Max [VerfasserIn]   i
 Booken, Nina [VerfasserIn]   i
 Hansen, Inga [VerfasserIn]   i
 Blanchard, Maël [VerfasserIn]   i
 Guenova, Emmanuella [VerfasserIn]   i
 Assaf, Chalid [VerfasserIn]   i
 Goerdt, Sergij [VerfasserIn]   i
 Nicolay, Jan Peter [VerfasserIn]   i
Titel:Mogamulizumab combined with extracorporeal photopheresis as a novel therapy in erythrodermic cutaneous T-cell lymphoma
Verf.angabe:Nadia Ninosu, Susanne Melchers, Max Kappenstein, Nina Booken, Inga Hansen, Maël Blanchard, Emmanuella Guenova, Chalid Assaf, Sergij Goerdt and Jan P. Nicolay
Jahr:2024
Umfang:13 S.
Illustrationen:Illustrationen
Fussnoten:Veröffentlicht: 27. Dezember 2023 ; Gesehen am 07.05.2024
Titel Quelle:Enthalten in: Cancers
Ort Quelle:Basel : MDPI, 2009
Jahr Quelle:2024
Band/Heft Quelle:16(2024), 1, Artikel-ID 141, Seite 1-13
ISSN Quelle:2072-6694
Abstract:Background: Primary cutaneous T-cell lymphomas (CTCLs) are rare lymphoproliferative malignancies characterized by significant morbidity and mortality in advanced disease stages. As curative approaches apart from allogeneic stem cell transplantation are lacking, establishing new treatment options, especially combination therapies, is crucial. Methods: This retrospective study included 11 patients with SS or MF receiving therapy with mogamulizumab in combination with ECP from four European expert centers. The response rates in the skin and blood as well as treatment use and adverse events (AE) were described. Results: 8/11 patients (73%) showed an overall response (OR) in the skin. The mean mSWAT decreased from 98.2 ± 40.8 to 34.6 ± 23.8. The overall response rate (ORR) in the blood was 64% with two complete responses. During combination therapy, the mean number of Sézary cells decreased from 3365.3 × 106/L before treatment to 1268.6 × 106/L. The mean minimum known period without progress was 7.2 months in the skin and 7.6 months in the blood. The most common AEs were mogamulizumab-associated rash (MAR) (45.5%), anemia (27.3%), lymphocytopenia (27.8%), and infusion related reaction (16.7%). No AE led to treatment discontinuation. Conclusions: Our study presents the combination of mogamulizumab and ECP as an effective therapy in the blood and skin in CTCL with good tolerability, similar to mogamulizumab monotherapy.
DOI:doi:10.3390/cancers16010141
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.3390/cancers16010141
 Volltext: https://www.mdpi.com/2072-6694/16/1/141
 DOI: https://doi.org/10.3390/cancers16010141
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:CTCL
 extracorporeal photopheresis
 mogamulizumab
 mycosis fungoides
 Sézary syndrome
K10plus-PPN:1888005556
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69211945   QR-Code
zum Seitenanfang